Growth Metrics

Gilead Sciences (GILD) EBT (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 24.16%
Dec 31, 2025 -42.93%
Sep 30, 2025 49.90%
Jun 30, 2025 47.30%
Mar 31, 2025 -23.90%
Dec 31, 2024 126.67%
Sep 30, 2024 -53.43%
Jun 30, 2024 145.76%
Mar 31, 2024 -371.39%
Dec 31, 2023 -28.69%
Sep 30, 2023 45.97%
Jun 30, 2023 22.15%
Mar 31, 2023 -35.99%
Dec 31, 2022 -16.49%
Sep 30, 2022 61.81%
Jun 30, 2022 1,088.82%
Mar 31, 2022 -120.03%
Dec 31, 2021 -77.92%
Sep 30, 2021 89.21%
Jun 30, 2021 -19.74%
Mar 31, 2021 24.81%
Dec 31, 2020 119.88%
Sep 30, 2020 127.75%
Jun 30, 2020 -248.43%
Mar 31, 2020 5.37%
Dec 31, 2019 226.65%
Sep 30, 2019 -162.28%
Jun 30, 2019 2.55%
Mar 31, 2019 131.30%
Dec 31, 2018 -61.86%
Sep 30, 2018 27.71%
Jun 30, 2018 2.61%
Mar 31, 2018 -4.37%
Dec 31, 2017 -42.09%
Sep 30, 2017 -10.79%
Jun 30, 2017 13.77%
Mar 31, 2017 -7.73%
Dec 31, 2016 -8.33%
Sep 30, 2016 -2.80%
Jun 30, 2016 -2.29%
Mar 31, 2016 -17.20%
Dec 31, 2015 -0.64%
Sep 30, 2015 -0.71%
Jun 30, 2015 5.19%
Mar 31, 2015 23.85%
Dec 31, 2014 25.48%
Sep 30, 2014 -21.71%
Jun 30, 2014 46.02%
Mar 31, 2014 165.06%
Dec 31, 2013 3.04%
Sep 30, 2013 0.38%
Jun 30, 2013 14.41%
Mar 31, 2013 -8.05%
Dec 31, 2012 7.51%
Sep 30, 2012 -1.91%
Jun 30, 2012 44.97%
Mar 31, 2012 -18.32%
Dec 31, 2011 -16.01%
Sep 30, 2011 -0.77%
Jun 30, 2011 12.35%
Mar 31, 2011 9.39%
Dec 31, 2010 -16.81%
Sep 30, 2010 -3.23%
Jun 30, 2010 -14.37%
Mar 31, 2010 9.48%
Dec 31, 2009 18.88%
Sep 30, 2009 17.96%
Jun 30, 2009 -5.06%